Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
Authors' conclusion
Our clinical trial data support the immunogenicity and safety of a third COVID-19 vaccination in patients with IMIDs.
Study context
- Population
- Immunosuppressed patients with immune-mediated inflammatory diseases (IMIDs) and healthy controls receiving a third COVID-19 mRNA vaccination
- Participants
- 60 vs 48
- Comparison
- Third mRNA COVID-19 vaccination in patients with IMIDs vs healthy controls
- IMIDsn = 60
- Healthy controls (HCs)n = 48reference
- Outcome
- Anti-RBD antibody levels >1500 BAU/mL in patients with IMIDs vs HCs
Main finding
As reported in the abstract
Anti-RBD antibodies >1500 BAU/mL after third vaccination
P = 0.101
Further findings
| Outcome | P value |
|---|---|
| Anti-RBD and neutralising antibody levels after third vaccinationIMIDs vs HCs · anti-RBD levels significantly lower in IMIDs | P = 0.002 |
| Anti-RBD and neutralising antibody levels after third vaccinationIMIDs vs HCs · neutralising antibody levels significantly lower in IMIDs | P = 0.016 |
Fold increase in antibody levels, week 0 to 4
- Higher in patients with IMIDs
Antibody levels by disease-modifying anti-rheumatic drugs (DMARD) therapy
- bDMARD or bDMARD + csDMARD combination associated with reduced antibody levels
Cellular immune response to wild type and Omicron peptide stimulation
- Enhanced after the third vaccination
Safety
Serious adverse events attributed to third vaccination · week 4
- No serious adverse event attributed to the third vaccination
- Reactogenicity recorded for 7 days
Original publication
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls. Ann Rheum Dis. Published 15 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →